Literature DB >> 7535736

Cellular immune responses in patients with dual infection of hepatitis B and C viruses: dominant role of hepatitis C virus.

S L Tsai1, Y F Liaw, C T Yeh, C M Chu, G C Kuo.   

Abstract

Several lines of evidence have suggested that immune mechanisms are involved in the pathogenesis of hepatitis B virus (HBV)- and hepatitis C virus (HCV)-related hepatitis. Study of patients with dual HBV and HCV infection raises the question of which is etiologically more relevant in determining the liver cell damage. To address this issue, proliferation of peripheral blood mononuclear cells (PBMCs) in response to a panel of HBV and HCV antigens was assayed in 13 patients with chronic dual hepatitis B and C, 7 patients with chronic hepatitis B, 7 patients with chronic hepatitis C, and 6 patients with hepatitis B surface antigen (HBsAg) carrier state. Although HBV or HCV hepatitis patients had a significant response to HBV or HCV antigens, respectively, the patients with dual hepatitis B and C exclusively responded to HCV antigens, but not to HBV antigens. One patients who was seropositive for both HBV-DNA and HCV-RNA showed a low response to HBV antigens initially but lost the response 3 months later and became responsive to more HCV antigens. These findings suggest that HCV has a dominant role in the immune response of the patients with dual HBV and HCV infection.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7535736

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  6 in total

1.  Prevalence of anti-HCV antibodies in chronic liver disease in the Czech Republic.

Authors:  J Stránský; M Horejsová; A Chlumská; E Honzáková; J Vandasová; V Nĕmecek
Journal:  Infection       Date:  1997 Jan-Feb       Impact factor: 3.553

Review 2.  HBV plus HCV, HCV plus HIV, HBV plus HIV.

Authors:  James S Park; Neeraj Saraf; Douglas T Dieterich
Journal:  Curr Gastroenterol Rep       Date:  2006-02

3.  A study-screening of blood donors for blood transmissible diseases.

Authors:  S V Shinde; G V Puranik
Journal:  Indian J Hematol Blood Transfus       Date:  2008-03-19       Impact factor: 0.900

4.  Sequential immunological analysis of HBV/HCV co-infected patients during Peg-IFN/RBV therapy.

Authors:  Yasuteru Kondo; Yoshiyuki Ueno; Masashi Ninomiya; Keiichi Tamai; Yasuhito Tanaka; Jun Inoue; Eiji Kakazu; Koju Kobayashi; Osamu Kimura; Masahito Miura; Takeshi Yamamoto; Tomoo Kobayashi; Takehiko Igarashi; Tooru Shimosegawa
Journal:  J Gastroenterol       Date:  2012-05-16       Impact factor: 7.527

5.  Dual Infection with Hepatitis B and Epstein-Barr Virus Presenting with Severe Jaundice, Coagulopathy, and Hepatitis B Virus Chronicity Outcome.

Authors:  Sirish C Rao; Imran Ashraf; Fazia Mir; Sami Samiullah; Jamal A Ibdah; Veysel Tahan
Journal:  Am J Case Rep       Date:  2017-02-16

6.  Circulating Th1 and Th2 cytokines in patients with hepatitis C virus infection.

Authors:  X G Fan; W E Liu; C Z Li; Z C Wang; L X Luo; D M Tan; G L Hu; Z Zhang
Journal:  Mediators Inflamm       Date:  1998       Impact factor: 4.711

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.